CORT
Price
$52.40
Change
-$2.74 (-4.97%)
Updated
Dec 18, 04:59 PM (EDT)
56 days until earnings call
MDXG
Price
$9.12
Change
-$0.41 (-4.30%)
Updated
Dec 18, 04:59 PM (EDT)
76 days until earnings call
Ad is loading...

CORT vs MDXG

Header iconCORT vs MDXG Comparison
Open Charts CORT vs MDXGBanner chart's image
Corcept Therapeutics
Price$52.40
Change-$2.74 (-4.97%)
Volume$13.73K
CapitalizationN/A
MiMedx Group
Price$9.12
Change-$0.41 (-4.30%)
Volume$9.64K
CapitalizationN/A
CORT vs MDXG Comparison Chart
Loading...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CORT vs. MDXG commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Hold and MDXG is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CORT: $55.14 vs. MDXG: $9.53)
Brand notoriety: CORT and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CORT: 60% vs. MDXG: 75%
Market capitalization -- CORT: $5.78B vs. MDXG: $1.4B
CORT [@Biotechnology] is valued at $5.78B. MDXG’s [@Biotechnology] market capitalization is $1.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CORT’s FA Score shows that 2 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • CORT’s FA Score: 2 green, 3 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, CORT is a better buy in the long-term than MDXG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CORT’s TA Score shows that 4 TA indicator(s) are bullish while MDXG’s TA Score has 3 bullish TA indicator(s).

  • CORT’s TA Score: 4 bullish, 4 bearish.
  • MDXG’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CORT is a better buy in the short-term than MDXG.

Price Growth

CORT (@Biotechnology) experienced а -6.24% price change this week, while MDXG (@Biotechnology) price change was -2.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

CORT is expected to report earnings on Feb 12, 2025.

MDXG is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($5.78B) has a higher market cap than MDXG($1.4B). CORT has higher P/E ratio than MDXG: CORT (41.59) vs MDXG (16.72). CORT YTD gains are higher at: 69.766 vs. MDXG (8.666). CORT has higher annual earnings (EBITDA): 145M vs. MDXG (66.8M). CORT has more cash in the bank: 380M vs. MDXG (88.8M). CORT has less debt than MDXG: CORT (6.79M) vs MDXG (19M). CORT has higher revenues than MDXG: CORT (629M) vs MDXG (343M).
CORTMDXGCORT / MDXG
Capitalization5.78B1.4B413%
EBITDA145M66.8M217%
Gain YTD69.7668.666805%
P/E Ratio41.5916.72249%
Revenue629M343M183%
Total Cash380M88.8M428%
Total Debt6.79M19M36%
FUNDAMENTALS RATINGS
CORT vs MDXG: Fundamental Ratings
CORT
MDXG
OUTLOOK RATING
1..100
7281
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
772
SMR RATING
1..100
3812
PRICE GROWTH RATING
1..100
3740
P/E GROWTH RATING
1..100
1675
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDXG's Valuation (72) in the Biotechnology industry is in the same range as CORT (80) in the Pharmaceuticals Other industry. This means that MDXG’s stock grew similarly to CORT’s over the last 12 months.

CORT's Profit vs Risk Rating (7) in the Pharmaceuticals Other industry is somewhat better than the same rating for MDXG (72) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than MDXG’s over the last 12 months.

MDXG's SMR Rating (12) in the Biotechnology industry is in the same range as CORT (38) in the Pharmaceuticals Other industry. This means that MDXG’s stock grew similarly to CORT’s over the last 12 months.

CORT's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as MDXG (40) in the Biotechnology industry. This means that CORT’s stock grew similarly to MDXG’s over the last 12 months.

CORT's P/E Growth Rating (16) in the Pharmaceuticals Other industry is somewhat better than the same rating for MDXG (75) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than MDXG’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CORTMDXG
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
66%
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Ad is loading...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QJUN28.69-0.06
-0.21%
FT Vest Nasdaq-100 Buffer ETF - Jun
FICS34.90-0.11
-0.31%
First Trust Intl Developed Cap Strth ETF
SURE119.96-1.30
-1.07%
AdvisorShares Insider Advantage ETF
IYF112.49-1.27
-1.12%
iShares US Financials ETF
GCAD34.87-0.51
-1.44%
Gabelli Commercial Aerospace & Dfns ETF

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+0.63%
AXON - MDXG
47%
Loosely correlated
-2.09%
NTLA - MDXG
45%
Loosely correlated
-1.87%
EDIT - MDXG
42%
Loosely correlated
+2.70%
VCYT - MDXG
42%
Loosely correlated
-2.52%
AVXL - MDXG
41%
Loosely correlated
+0.33%
More